Arcellx Announces Presentation of Positive Clinical Results from Ongoing Phase 1 Study of CART-ddBCMA at the 2021 ASCO Annual Meeting
100% (12/12) of patients with relapsed and refractory multiple myeloma treated with Arcellx’s BCMA-specific CAR-modified T-cell therapy achieved responses per...